CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib

Biopharmaceutics & Drug Disposition
Stefan De BuckRalph Woessner

Abstract

This study investigated the effect of itraconazole, a strong dual inhibitor of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), on the single dose pharmacokinetics of leniolisib. In order to differentiate the specific contribution of CYP3A from P-gp, the potential interaction with quinidine, a strong inhibitor of P-gp but not CYP3A, was studied as well. Using a fixed-sequence, 3-way crossover design, 20 healthy male subjects received single oral doses of 10 mg leniolisib during three phases separated by a washout: (1) leniolisib alone, (2) 200 mg itraconazole once daily for 9 days plus leniolisib on day 5, and (3) 300 mg quinidine administered 1 h before and 3 h after leniolisib. Itraconazole increased the leniolisib oral drug exposure (AUCinf ) by on average 2.1-fold, whereas the peak drug concentration (Cmax ) was less impacted (1.25-fold). The terminal elimination half-life (T1/2 ) of leniolisib was also increased by ~2-fold. Neither oral AUCinf nor Cmax or T1/2 was found to be altered by quinidine. These findings suggest that the interaction with itraconazole occurred mainly systemically through inhibition of CYP3A, and corroborate our in vitro findings that leniolisib is neither a sensitive CYP3A substrate nor a releva...Continue Reading

References

Nov 1, 1991·Clinical Pharmacology and Therapeutics·J H SchellensD D Breimer
Feb 1, 1990·British Journal of Clinical Pharmacology·K BrøsenL F Gram
Mar 1, 1990·British Journal of Clinical Pharmacology·M D NielsenL F Gram
Sep 1, 1988·Antimicrobial Agents and Chemotherapy·T C HardinJ G Kuhn
May 1, 1994·Clinical Pharmacology and Therapeutics·K T OlkkolaP J Neuvonen
Oct 23, 1997·Clinical Pharmacology and Therapeutics·K T KivistöP J Neuvonen
Jan 8, 1998·Therapeutic Drug Monitoring·K M JalavaP J Neuvonen
Dec 2, 1999·Experimental Cell Research·E S Kandel, N Hay
Dec 14, 1999·British Journal of Clinical Pharmacology·K E KenworthyJ B Houston
Oct 3, 2000·Clinical Pharmacology and Therapeutics·A J SadequeA J Wood
Jul 2, 2004·Clinical Pharmacology and Therapeutics·Reinhard DingWalter E Haefeli
Aug 25, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Tsukasa UnoTomonori Tateishi
Dec 17, 2009·Basic & Clinical Pharmacology & Toxicology·Leslie Z Benet
Dec 15, 2010·British Journal of Clinical Pharmacology·Eleanor J GuestAleksandra Galetin
Jan 22, 2013·Annual Review of Immunology·Klaus Okkenhaug
Apr 12, 2014·Clinical Pharmacology and Therapeutics·M BosilkovskaY Daali
Oct 27, 2016·Nature Reviews. Immunology·Carrie L LucasKlaus Okkenhaug
Sep 28, 2017·ACS Medicinal Chemistry Letters·Klemens HoegenauerChristoph Burkhart

❮ Previous
Next ❯

Citations

Aug 26, 2020·Expert Opinion on Drug Metabolism & Toxicology·Gabriel TaoRomi Ghose
Dec 20, 2021·Therapeutic Drug Monitoring·Benjamin KablyEliane M Billaud

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Related Papers

Journal of Clinical Pharmacology
Hao XiongDarryl J Sleep
Basic & Clinical Pharmacology & Toxicology
Pieter J SwartNeila N Smith
Therapeutic Drug Monitoring
K M JalavaP J Neuvonen
© 2022 Meta ULC. All rights reserved